Drug intelligence / Profile preview

NNC4004-0002

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Subcutaneous Injection

Overview

NNC4004-0002 is an investigational uricosuric drug developed by Novo Nordisk for the treatment of asymptomatic hyperuricemia. It is a new molecular entity currently in Phase 1 clinical trials, with its first administration to humans occurring in these studies. The primary aim of ongoing research is to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses administered subcutaneously in adults with asymptomatic hyperuricemia. The drug’s mechanism of action has not been publicly defined but it is classified as a uricosuric agent, suggesting it acts to lower serum uric acid levels by promoting renal excretion[1][2][3][5].

Other names: NNC4004 0002NNC-4004 0002NNC 4004 0002

Beyond the preview

Go deeper on NNC4004-0002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC4004-0002.

Explore the full profile